Attorney Docket No.: 0925.009/11862US09

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:	) CERTIFICATION UNDER 37 CFR § 1.10
deBoer, et al.	) I hereby certify that this Continuing
U.S. Serial No.:	Application Transmittal Under 37 CFR § 1.53(b) and the documents referred to as enclosed therewith are being deposited with
Filed: September 18, 2001	) the United States Postal Service on September 18, 2001, in an envelope
For: "Method for Treating An IgE- Mediated Disease In A Patient Using Anti-CD40 Monoclonal Antibodies" (As Amended)	addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 202331 utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service Under Mailing Label No. EL 849006685
Group Art Unit:	
Examiner:	Jimmie Blackburn

# PRELIMINARY AMENDMENT

Box Patent Application Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

The Applicants respectfully request that the Examiner make the following amendments to the specification and the claims before considering the prosecution on the merits.

In the Title:

Please delete the title and substitute therefore:

--Method For Treating An IgE-Mediated Disease In A Patient Using Anti-CD40 Monoclonal Antibodies--.



# In the Figures:

Please replace Figs. 1A, 1B and 2, with substitute Figs. 1A, 1B and 2, respectively, as attached hereto. A copy of each of Figs. 1A, 1B and 2, showing the proposed changes in red is also attached hereto.

## In the Specification:

At page 1, delete lines 4-7.

Please insert at the end of the specification the three pages of the SEQUENCE LISTING, as attached to the Combined Statement that is cofiled herewith.

### In the Claims:

Please delete claims 1-5, 7, 12-28 in the specification as filed.

Please add claims 29 and 30.

A copy of substitute claim 6, and all pending claims (*i.e.*, claims 6, 8-11 and 29-30) is shown on Exhibit A. A marked up copy of original claim 6, showing the changes made to arrive at substitute claim 6, is attached hereto as Exhibit B.

#### REMARKS

The amendments to the specification do not add new matter. In particular, the amendment to the specification at page 1, lines 5-6 merely conforms the specification to the current rule wherein the claim of priority need not be cited on the first page.

The amendments to the Figures also do not add new matter. In particular, the Applicants submit substitute Figures 1A, 1B and 2, which are already attached to the specification. A copy of original Figures 1A, 1B and 2, containing the changes shown in red, are attached hereto as Exhibit C. Specifically, substitute Figures 1A and 2 now contain the SEQ ID NOs of the nucleotide sequences disclosed therein. Substitute Figure